ANTIHYPERTENSIVE, ORGAN PROTECTIVE, AND METABOLIC EFFICIENCY OF SPIRAPRIL IN PATIENTS WITH ARTERIAL HYPERTENSION

<p><strong>Aim.</strong> To estimate antihypertensive, organ protective and metabolic efficiency of angiotensin converting enzyme (ACE) inhibitor spirapril in patients with arterial hypertension (AH).</p><p><strong>Material and methods.</strong> 30 patients...

Full description

Bibliographic Details
Main Authors: M. V. Leonova, M. A. Demidova, A. V. Tarasov, Y. V. Belousov
Format: Article
Language:English
Published: Столичная издательская компания 2015-12-01
Series:Рациональная фармакотерапия в кардиологии
Subjects:
Online Access:http://www.rpcardio.ru/jour/article/view/346
_version_ 1797713445791989760
author M. V. Leonova
M. A. Demidova
A. V. Tarasov
Y. V. Belousov
author_facet M. V. Leonova
M. A. Demidova
A. V. Tarasov
Y. V. Belousov
author_sort M. V. Leonova
collection DOAJ
description <p><strong>Aim.</strong> To estimate antihypertensive, organ protective and metabolic efficiency of angiotensin converting enzyme (ACE) inhibitor spirapril in patients with arterial hypertension (AH).</p><p><strong>Material and methods.</strong> 30 patients with AH of I-II grade with different cardiovascular risk were included into the study. Spirapril was prescribed in the dose of 3 mg once daily. If necessary, daily dose could be increased to 6 mg after two weeks, and after next 4 weeks hydrochlorothiazide in daily dose 12,5-25 mg could be added. Treatment lasted 16 weeks. Before and after 16-week treatment ambulatory blood pressure monitoring (ABPM) was carried out. At the same time vasodilatation tests for reactive hyperemia and nitroglycerin were held, microalbuminuria and β2-microglobulinuria levels were defined, figures of lipid and glucose metabolism were studied, questionnaires for quality of life were filled in.</p><p><strong>Results.</strong> 27 patients with AH finished the study according to protocol. Treatment with spirapril within 16 weeks caused normalization of blood pressure in 60% of patients, decreased levels of microalbuminuria (p&lt;0,05) and β2-microglobulinuria (p&lt;0,05), recovered significantly disrupted endothelial function according to the results of vasodilatation tests (p&lt;0,01), improved patients quality of life (p&lt;0,05). Spirapril didn’t change lipid and glucose metabolism, regardless that in 1/3 of cases it was used in combination with hydrochlorothiazide.</p><p><strong>Conclusion.</strong> Spirapril is a highly efficient antihypertensive drug with organ protective effect and metabolic neutrality. According to the revealed qualities it can be recommended to patients with AH with high cardiovascular risk.</p>
first_indexed 2024-03-12T07:36:43Z
format Article
id doaj.art-cc150e9796ff4419b3f98cc8af7f17bc
institution Directory Open Access Journal
issn 1819-6446
2225-3653
language English
last_indexed 2024-03-12T07:36:43Z
publishDate 2015-12-01
publisher Столичная издательская компания
record_format Article
series Рациональная фармакотерапия в кардиологии
spelling doaj.art-cc150e9796ff4419b3f98cc8af7f17bc2023-09-02T21:31:56ZengСтоличная издательская компанияРациональная фармакотерапия в кардиологии1819-64462225-36532015-12-01124810.1234/1819-6446-2005-2-4-8346ANTIHYPERTENSIVE, ORGAN PROTECTIVE, AND METABOLIC EFFICIENCY OF SPIRAPRIL IN PATIENTS WITH ARTERIAL HYPERTENSIONM. V. Leonova0M. A. Demidova1A. V. Tarasov2Y. V. Belousov3Российский государственный медицинский университет, МоскваРоссийский государственный медицинский университет, МоскваРоссийский государственный медицинский университет, МоскваРоссийский государственный медицинский университет, Москва<p><strong>Aim.</strong> To estimate antihypertensive, organ protective and metabolic efficiency of angiotensin converting enzyme (ACE) inhibitor spirapril in patients with arterial hypertension (AH).</p><p><strong>Material and methods.</strong> 30 patients with AH of I-II grade with different cardiovascular risk were included into the study. Spirapril was prescribed in the dose of 3 mg once daily. If necessary, daily dose could be increased to 6 mg after two weeks, and after next 4 weeks hydrochlorothiazide in daily dose 12,5-25 mg could be added. Treatment lasted 16 weeks. Before and after 16-week treatment ambulatory blood pressure monitoring (ABPM) was carried out. At the same time vasodilatation tests for reactive hyperemia and nitroglycerin were held, microalbuminuria and β2-microglobulinuria levels were defined, figures of lipid and glucose metabolism were studied, questionnaires for quality of life were filled in.</p><p><strong>Results.</strong> 27 patients with AH finished the study according to protocol. Treatment with spirapril within 16 weeks caused normalization of blood pressure in 60% of patients, decreased levels of microalbuminuria (p&lt;0,05) and β2-microglobulinuria (p&lt;0,05), recovered significantly disrupted endothelial function according to the results of vasodilatation tests (p&lt;0,01), improved patients quality of life (p&lt;0,05). Spirapril didn’t change lipid and glucose metabolism, regardless that in 1/3 of cases it was used in combination with hydrochlorothiazide.</p><p><strong>Conclusion.</strong> Spirapril is a highly efficient antihypertensive drug with organ protective effect and metabolic neutrality. According to the revealed qualities it can be recommended to patients with AH with high cardiovascular risk.</p>http://www.rpcardio.ru/jour/article/view/346артериальная гипертензияспираприлэндотелиальная функциянефропротекциялипидыметаболизм глюкозы
spellingShingle M. V. Leonova
M. A. Demidova
A. V. Tarasov
Y. V. Belousov
ANTIHYPERTENSIVE, ORGAN PROTECTIVE, AND METABOLIC EFFICIENCY OF SPIRAPRIL IN PATIENTS WITH ARTERIAL HYPERTENSION
Рациональная фармакотерапия в кардиологии
артериальная гипертензия
спираприл
эндотелиальная функция
нефропротекция
липиды
метаболизм глюкозы
title ANTIHYPERTENSIVE, ORGAN PROTECTIVE, AND METABOLIC EFFICIENCY OF SPIRAPRIL IN PATIENTS WITH ARTERIAL HYPERTENSION
title_full ANTIHYPERTENSIVE, ORGAN PROTECTIVE, AND METABOLIC EFFICIENCY OF SPIRAPRIL IN PATIENTS WITH ARTERIAL HYPERTENSION
title_fullStr ANTIHYPERTENSIVE, ORGAN PROTECTIVE, AND METABOLIC EFFICIENCY OF SPIRAPRIL IN PATIENTS WITH ARTERIAL HYPERTENSION
title_full_unstemmed ANTIHYPERTENSIVE, ORGAN PROTECTIVE, AND METABOLIC EFFICIENCY OF SPIRAPRIL IN PATIENTS WITH ARTERIAL HYPERTENSION
title_short ANTIHYPERTENSIVE, ORGAN PROTECTIVE, AND METABOLIC EFFICIENCY OF SPIRAPRIL IN PATIENTS WITH ARTERIAL HYPERTENSION
title_sort antihypertensive organ protective and metabolic efficiency of spirapril in patients with arterial hypertension
topic артериальная гипертензия
спираприл
эндотелиальная функция
нефропротекция
липиды
метаболизм глюкозы
url http://www.rpcardio.ru/jour/article/view/346
work_keys_str_mv AT mvleonova antihypertensiveorganprotectiveandmetabolicefficiencyofspiraprilinpatientswitharterialhypertension
AT mademidova antihypertensiveorganprotectiveandmetabolicefficiencyofspiraprilinpatientswitharterialhypertension
AT avtarasov antihypertensiveorganprotectiveandmetabolicefficiencyofspiraprilinpatientswitharterialhypertension
AT yvbelousov antihypertensiveorganprotectiveandmetabolicefficiencyofspiraprilinpatientswitharterialhypertension